Delayed
Nasdaq Stockholm
05:59:36 2024-05-14 am EDT
|
5-day change
|
1st Jan Change
|
21.25
SEK
|
+0.95%
|
|
+5.99%
|
+49.86%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
737.6
|
1,903
|
998.9
|
1,465
|
1,584
|
2,352
|
-
|
-
|
Enterprise Value (EV)
1 |
550
|
1,655
|
704.7
|
1,203
|
1,251
|
2,047
|
2,142
|
1,992
|
P/E ratio
|
-6.81
x
|
-11.6
x
|
-3.28
x
|
-4.49
x
|
-4.4
x
|
-12.9
x
|
-8.95
x
|
-17.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
45.2
x
|
5.98
x
|
15.1
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
39.4
x
|
5.45
x
|
12.8
x
|
EV / EBITDA
|
-5.93
x
|
-11.1
x
|
-2.42
x
|
-4.19
x
|
-4.89
x
|
-8.65
x
|
-12.3
x
|
-11.3
x
|
EV / FCF
|
-3.35
x
|
-13.3
x
|
-2.59
x
|
-5.33
x
|
-3.17
x
|
-41.8
x
|
-6.37
x
|
-10
x
|
FCF Yield
|
-29.8%
|
-7.51%
|
-38.6%
|
-18.8%
|
-31.5%
|
-2.39%
|
-15.7%
|
-9.99%
|
Price to Book
|
-
|
5.37
x
|
2.61
x
|
5.07
x
|
3.01
x
|
5.74
x
|
13.4
x
|
30.9
x
|
Nbr of stocks (in thousands)
|
50,175
|
60,418
|
71,760
|
81,848
|
111,723
|
111,723
|
-
|
-
|
Reference price
2 |
14.70
|
31.50
|
13.92
|
17.90
|
14.18
|
21.05
|
21.05
|
21.05
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/25/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
52
|
393.1
|
156
|
EBITDA
1 |
-92.68
|
-149.5
|
-291.2
|
-287.1
|
-255.5
|
-236.8
|
-173.7
|
-176.4
|
EBIT
1 |
-94.01
|
-149.5
|
-294.8
|
-290.7
|
-321.5
|
-237.6
|
-174.5
|
-176.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-456.94%
|
-44.39%
|
-113.06%
|
Earnings before Tax (EBT)
1 |
-93.33
|
-147.3
|
-296.7
|
-288.8
|
-311.3
|
-236.8
|
-173.6
|
-175.4
|
Net income
1 |
-93.08
|
-146.9
|
-296.5
|
-288.4
|
-310.9
|
-236.5
|
-173.4
|
-175.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-454.76%
|
-44.1%
|
-112.32%
|
EPS
2 |
-2.160
|
-2.710
|
-4.250
|
-3.990
|
-3.220
|
-1.628
|
-2.352
|
-1.215
|
Free Cash Flow
1 |
-164.1
|
-124.3
|
-272.2
|
-225.9
|
-394
|
-49
|
-336
|
-199
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-94.22%
|
-85.47%
|
-127.56%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/25/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-63.95
|
-65.18
|
-68.96
|
-64.22
|
-69.17
|
EBIT
1 |
-
|
-64.9
|
-66.1
|
-69.8
|
-65.06
|
-120.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-80.29
|
-
|
-66.38
|
-69.3
|
-63.66
|
-112
|
Net income
1 |
-80.4
|
-65.9
|
-66.3
|
-69.2
|
-63.56
|
-111.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.120
|
-
|
-0.8100
|
-0.8500
|
-0.5800
|
-1.000
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/22
|
8/25/22
|
5/4/23
|
8/24/23
|
11/2/23
|
2/28/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
188
|
249
|
294
|
262
|
334
|
304
|
210
|
360
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-164
|
-124
|
-272
|
-226
|
-394
|
-49
|
-336
|
-199
|
ROE (net income / shareholders' equity)
|
-30.7%
|
-43.4%
|
-80.4%
|
-85.8%
|
-83.5%
|
-58.6%
|
-84%
|
-19.3%
|
ROA (Net income/ Total Assets)
|
-29%
|
-39.3%
|
-69.1%
|
-73%
|
-74.5%
|
-55.5%
|
-126%
|
-16.8%
|
Assets
1 |
321.4
|
373.9
|
428.9
|
394.8
|
417.1
|
426.3
|
137.4
|
1,043
|
Book Value Per Share
2 |
-
|
5.870
|
5.340
|
3.530
|
4.720
|
3.670
|
1.570
|
0.6800
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/25/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
21.05
SEK Average target price
61.5
SEK Spread / Average Target +192.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +50.56% | 217M | | +5.66% | 111B | | +11.23% | 105B | | -2.30% | 21.93B | | -12.15% | 22.34B | | -5.43% | 18.59B | | -36.52% | 18.12B | | -10.09% | 16.96B | | +3.33% | 13.7B | | +36.58% | 12.45B |
Bio Therapeutic Drugs
|